Skip to content
GLP-1 Savers
Menu
Ranked #106 · Watch List

Pallas Health review

Names its six dispensing pharmacies and two prescribing physicians' NPI numbers — disclosure almost nobody in this category offers — and then sells the whole thing on a single 12-week prepay whose advertised "$199/mo average" is that prepay divided by three, with no monthly rung to pick instead.

Est. first month

$199/mo (Pallas's own average for $597 billed every 12 weeks — its only cadence)

Save ~85% vs brand-name
Get this deal Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Value Score.
Pricing to watch. There is no monthly plan. The funnel renders no term selector at all: semaglutide is $139 for the first four weeks and then $597 billed every 12 weeks, so the second charge is $597 in one payment four weeks after the first — tirzepatide, $179 then $897. The advertised "$199/mo average" is that 12-week prepay divided by three. And the divisor is off: an 84-day cycle comes round 4.35 times a year rather than four, so on Pallas's own renewal terms semaglutide costs $2,527 in year one ($210.58/mo) and about $2,596 a year after that (~$216/mo), and tirzepatide $3,767 then about $3,900 (~$325/mo) — roughly 8.7% above the advertised average. A sitewide "Up to $120 off your first month" banner is a discount, not a price.
Semaglutide
$199/mo average — Pallas's own figure for $597 billed every 12 weeks, its only cadence; $139 covers the first 4 weeks
Tirzepatide
$299/mo average — Pallas's own figure for $897 billed every 12 weeks, its only cadence; $179 covers the first 4 weeks
Coverage
All 50 states and Washington D.C. — asynchronous in 43; Arkansas, Mississippi, New Mexico, North Dakota, Rhode Island, South Dakota, West Virginia and D.C. require one video visit
Brand-name
Yes

The Value Score card

Pallas Health scored on our six published factors. See the methodology.

Lowest Real Price72/100
No Teaser-Rate Bait55/100
Nationwide Availability96/100
Both Molecules88/100
Easy Cancellation70/100
Reputation78/100

Why it's a deal

  • Names all six dispensing pharmacies in public — Belmar, Strive, Epiq Scripts, Casa Pharma Rx, The Pharmacy Hub and Foothills — with the 503A and 503B distinction explained, where almost everything else on this board names none
  • Names two prescribing physicians with their NPI numbers and links to the federal NPPES registry so you can check them yourself: Dr. Ana Lisa Carr, MD (family medicine, NPI-verified, licensed in 15 states) and Dr. Kelly Tenbrink, MD (emergency medicine, NPI-verified, Tennessee and Florida). Pallas additionally claims obesity and addiction medicine board certifications for Dr. Carr, which the registry does not carry either way
  • The advertised price is the checkout price. The homepage FAQ, the landing pages, the treatment pages and the live funnel all state the same four figures, and no different number appears at the medication-select screen — the badge-versus-checkout gap this site keeps finding elsewhere is absent here
  • Both compounded molecules plus a real brand-name route on the same desk: Zepbound at $1,069/mo, Ozempic $1,299, Wegovy $1,349 and Mounjaro $1,349, cash-pay and billed monthly rather than quarterly
  • Publishes its coverage precisely instead of as a blanket promise — all 50 states and D.C., fully asynchronous in 43, with the eight jurisdictions needing a video visit named one by one, and a shipping-state check built into the checkout
  • Leaving is self-serve and free: a cancellation portal, a pre-renewal email reminder, no minimum term, at least 30 days' notice before any price change, and a full refund if a clinician declines you. LegitScript Healthcare Merchant Certified (seal 49989444, which resolves while invented control IDs do not), and clean against FDA's live warning-letter database under its own name, its domain and its operator Brentmoor, Inc.

Read the fine print

  • ⚠ There is no month-to-month rung and no term selector at all. Semaglutide is $139 for the first four weeks and then $597 billed every 12 weeks — the second charge is the full $597, in one payment, four weeks after the first — and tirzepatide is $179 then $897. The advertised "$199/mo average" is that 12-week prepay divided by three, not a price anyone is billed
  • Twelve weeks is not three months. On Pallas's own published renewal terms the charge recurs every 84 days, which is 4.35 times a year rather than four, so semaglutide's first year is $2,527 ($210.58/mo) and the steady state is about $2,596 a year (~$216/mo) against $199 advertised; tirzepatide runs $3,767 then about $3,900 (~$325/mo) against $299. The advertised average understates the ongoing rate by roughly 8.7%
  • The $139 and $179 headline numbers are intro rates, and the sitewide "Up to $120 off your first month" banner is a discount rather than a price
  • One of the six named pharmacies, Belmar, received an FDA warning letter issued 31 March 2023 (posted 18 April 2023), addressed to "Belmar Pharma Solutions, Drug Depot, LLC., dba APS Pharmacy", over compounding practices — and FDA closed that letter out on 30 October 2023. Pallas itself carries no FDA warning letter under its own name, its domain or its operating company
  • Only two clinicians are named across the whole site, and the footer's "Provider directory" link resolves to a section naming the same two. The actual prescribing network — Lion MD's affiliated professional corporations — is not published
  • Money terms worth reading before you pay: $5 is deducted from each refunded payment for purchases made on or after 14 July 2026 (never on clinician-declined or unfulfilled orders, which refund in full), and the $60 visit deposit can be retained if you neither attend nor reschedule the required video visit in the eight jurisdictions that need one
  • Compounded semaglutide and tirzepatide are not FDA-approved and are not generic equivalents, which Pallas does disclose properly. Cash-pay only, with no insurance accepted ever, so the brand-name route at $1,069–$1,349/mo is far above what an insured patient pays
  • Several things a buyer would want are simply not published: whether baseline or follow-up lab work is included or charged extra, and whether the price rises with dose (there is no pre-purchase dose selector). The footer states that some site content is AI-generated with no warranty of accuracy, the advertised "4.8" rating carries no published source, and the before-and-after "Verified Customer" stories carry Pallas's own caveat that the individuals shown may be actors or models

The bottom line

Best for: Readers who want unusually specific disclosure about who prescribes and who dispenses, want the option of brand-name Zepbound or Wegovy from the same desk, and can absorb a $597 charge four weeks after the $139 one. Names its six dispensing pharmacies and two prescribing physicians' NPI numbers — disclosure almost nobody in this category offers — and then sells the whole thing on a single 12-week prepay whose advertised "$199/mo average" is that prepay divided by three, with no monthly rung to pick instead.

Ranked #106 of 390 programs we track — see our #1 deal, CoreAge Rx, for comparison.

Get this deal

Compare with other deals

The programs scoring closest to Pallas Health, out of 389 others we track.

Shopping Pallas Health against a specific rival? We put it head to head with our top-scoring pick on CoreAge Rx vs Pallas Health, and every program that undercuts or outscores it is ranked on the Pallas Health alternatives board.

More programs we track (24)

359 more are reviewed too — see every GLP-1 program we track, ranked.

Pricing and coverage on this page were read from Pallas Health's own website on ; the Value Score is our editorial judgment per the methodology. “% vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on Pallas Health's site. Not medical advice; see our disclosure.

← Back to all deals